Sanofi’s FREXALT Study is looking for people with relapsing forms of multiple sclerosis (RMS) to take part. The purpose of the study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide.

This 48-week study is to determine the efficacy and safety when switching from your current DMT to ublituximab and to determine if giving it over a shorter infusion time is safe and tolerable. If transitioning from another anti-CD20 therapy you may be eligible for a modified dosing schedule to eliminate the initial 150 mg dose of ublituximab.